Praxis Precision Medicines Dividends and Buybacks
Dividend criteria checks 0/6
Praxis Precision Medicines does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-14.2%
Buyback Yield
| Total Shareholder Yield | -14.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback
Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause. Analyst Commentary Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine.Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen
Summary Praxis Precision Medicines, Inc. maintains a Strong Buy rating, driven by two accepted NDAs with PDUFA target action dates and multiple late-stage catalysts in rare CNS disorders. Company has PDUFA dates for relutrigine [Sept 2026, SCN2A/SCN8A DEEs] and ulixacaltamide [Jan 2027, essential tremor], with potential label expansion for relutrigine in broad DEEs underway. Breakthrough Therapy Designation for elsunersen in early-onset SCN2A-DEE and robust phase 1/2 data [77% seizure reduction] provide another high-value pipeline asset. PRAX holds $1.4B in cash, funding operations into 2028, with additional $250M ATM flexibility and quarterly burn of ~$106M. Read the full article on Seeking AlphaWe're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking AlphaPraxis Precision Medicines: Multiple Potential Drivers
Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking AlphaPraxis Precision Medicines: Great Price Movement, But Still Not Convinced
Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking AlphaPraxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Summary Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Phase 2b study targeting this very same patient population to be initiated 2nd half of 2024. With cash on hand, plus underwritten public offering that brought in $161.7 million in cash, Praxis Precision Medicines believes it can fund its operations into 2026. Read the full article on Seeking AlphaStability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PRAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRAX's dividend payments have been increasing.
Dividend Yield vs Market
| Praxis Precision Medicines Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PRAX) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.1% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (PRAX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PRAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PRAX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PRAX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 19:20 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Praxis Precision Medicines, Inc. is covered by 28 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |